Company intelligence / Profile preview

4BIO Capital

London, England, United Kingdom4biocapital.com ↗

Ownership: Private
Employees: ~17
Development stage: Other

Overview

4BIO Capital is an international venture capital firm focused exclusively on advanced and emerging therapies. It supports and grows early-stage life science companies developing potentially curative treatments for high unmet medical needs. Its investments span cell and gene therapy, RNA-based therapeutics, targeted therapies such as antibody-drug conjugates and CAR-Ts, as well as microbiome approaches. The team comprises leading scientists and experienced investors with deep sector expertise.

Modalities: Cell therapyGene therapyRNA-based therapyTargeted therapiesMicrobiome-based therapies
Industry: Investors

Partnerships

Eli Lilly & Company (via ViaNautis)UCB Ventures S.A.Cystic Fibrosis FoundationTaiho Pharmaceutical Co., Ltd. (via Araris acquisition)

Beyond the preview

Go deeper on 4BIO Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4BIO Capital.

Explore the full profile